Sherwin-Williams High-Performance Flooring announced the launch of Accelera One, a grout and topcoat technology for pharmaceutical manufacturing environments. The technology offers benefits for pharmaceutical, life sciences, R&D and biopharma manufacturing spaces. A next-generation, ultra-high solids coating formulated to minimize downtime, it can also enhance durability and support green building goals. Accelera One delivers rapid cure…
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
The PHARMAP 2025 Congress, marking its fiftgh anniversary, is expected to convene 350 pharmaceutical manufacturing specialists, technology innovators, and industry leaders from April 14-15, 2025 in Berlin . The event will draw global pharmaceutical firms including Bayer, MSD, F. Hoffmann-La Roche, and GSK. IT will feature more than 57 speakers across specialized tracks, including pharmaceutical…
Confidently navigate the transition from bench to batch
Facility design challenges for small biopharma startups For small biopharma startups, the leap from groundbreaking discoveries in the lab to full-scale drug production is both exhilarating and daunting. While scientific innovation drives initial success, translating laboratory methods into manufacturing processes presents challenges beyond technical expertise. For all of the hurdles both compliance and technical rigor…
Reckitt to make Mucinex in North Carolina
Reckitt Benckiser Group announced today that it is expanding its U.S. manufacturing footprint by acquiring a 310,000 ft² pharmaceutical site in Wilson, North Carolina. The Slough, U.K.–based company said it will invest £155 million ($200 million) to establish a manufacturing facility in Wilson to produce Mucinex tablets and liquids to meet increased U.S. demand. Reckitt…
Sanofi to invest €40 million to boost antibody production in France
Sanofi recently announced that it is investing €40 million in its Lyon Gerland bioproduction site as it seeks to bolster its position in the immunology space. The investment will support production in France of the transplant drug Thymoglubulin, including €25 million toward developing and manufacturing a second-generation version of the drug. The remaining €15 million…
How biometric ID is boosting security and efficiency in pharma manufacturing
A maker of pharma manufacturing workstations says wearable biometric ID products are solving a security and efficiency challenge. Traditionally, pharmaceutical manufacturers have used a complex patchwork of access points, workstations, and tools, according to Fremont, California–based Arista Corp. Think badges, passwords and more, with the potential for someone other than the intended operator to gain…
Otsuka partners with ICU Medical to enter U.S. IV products market
Otsuka Holdings will pay ICU Medical (Nasdaq: ICUI) an upfront payment of $200 million as part of a joint venture to enter the U.S. IV products market, which has been facing hurricane-related shortages this fall. The partnership — which involves ICU Medical providing commercial services for Otsuka’s Otsuka Pharmaceutical Factory (OPF) subsidiary — also includes…
MilliporeSigma invests $76M to expand cancer therapy manufacturing
MilliporeSigma, Merck KGaA’s U.S. and Canada Life Science business, announced a $76 million expansion of its ADC manufacturing capabilities and capacity. The company is expanding the capacity at its Bioconjugation Center of Excellence facility in St. Louis. This investment triples existing capacity and enhances the company’s contract development and manufacturing organization (CDMO) offering. MilliporeSigma said…
PharmaLogic opens new radiopharmaceutical production plant in Utah
PharmaLogic announced today that it opened a new radiopharmaceutical production and research facility in Salt Lake City. The new state-of-the-art facility marks “a major step forward” in the CDMO’s mission to deliver diagnostic and therapeutic radiopharmaceuticals to patients across North America, according to a news release. PharmaLogic said it chose to establish the facility in…
J&J invest $2B to build new manufacturing facility in North Carolina
Johnson & Johnson recently announced plans to invest more than $2 billion in a new manufacturing facility in North Carolina. The company plans to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina, to expand the production of its pipeline of innovative biologics. The expansion supports J&J’s broader plan to advance more than 70…